Connect Biopharma Holdings (CNTB)
(Delayed Data from NSDQ)
$2.00 USD
-0.02 (-0.99%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CNTB 2.00 -0.02(-0.99%)
Will CNTB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CNTB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTB
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now?
CNTB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CNTB
Connect Biopharma (CNTB) Expands Board with New Director Appointment | CNTB Stock News
Connect Biopharma (CNTB) Gains Attention with Promising Treatment | CNTB Stock News
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors | CNTB ...
Northland Begins Coverage on Connect Biopharma (CNTB) with Positive Outlook | CNTB Stock News
Connect Biopharma announces expansion of board, appoints Schoeneck as director